MARKET

VKTX

VKTX

Viking Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.69
+0.12
+1.83%
After Hours: 6.57 -0.13 -1.87% 17:55 09/17 EDT
OPEN
6.58
PREV CLOSE
6.57
HIGH
6.91
LOW
6.50
VOLUME
2.21M
TURNOVER
--
52 WEEK HIGH
10.09
52 WEEK LOW
4.951
MARKET CAP
523.09M
P/E (TTM)
-10.0996
1D
5D
1M
3M
1Y
5Y
Viking Therapeutics to Participate in Upcoming Investor Conferences
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming investor...
PR Newswire · 09/02 20:05
What Type Of Shareholders Own The Most Number of Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
If you want to know who really controls Viking Therapeutics, Inc. ( NASDAQ:VKTX ), then you'll have to look at the...
Simply Wall St. · 08/30 18:08
--Chardan Suspends Coverage on Viking Therapeutics at Buy Rating With $19 Price Target
MT Newswires · 08/02 11:21
Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat
Zacks.com · 07/30 17:18
Raymond James Maintains Outperform on Viking Therapeutics, Raises Price Target to $13
Raymond James analyst Steven Seedhouse maintains Viking Therapeutics (NASDAQ:VKTX) with a Outperform and raises the price target from $12 to $13.
Benzinga · 07/29 12:58
BRIEF-Viking Therapeutics Inc - Entered Into An ATM Equity Offering Sales Agreement Of Up To $125.0 Million Shares
reuters.com · 07/28 21:18
BRIEF-Viking Therapeutics Inc - Files For Mixed Shelf Of Up To $600 Million
reuters.com · 07/28 21:16
Viking Therapeutics shares fall after wider Q2 net loss
Viking Therapeutics (NASDAQ:VKTX) shares fall more than 2% post market after reporting a wider second-quarter net loss, primarily due to an increase in research and development expenses. For the three months ended June
Seekingalpha · 07/28 21:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VKTX. Analyze the recent business situations of Viking Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VKTX stock price target is 20.10 with a high estimate of 40.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 224
Institutional Holdings: 44.05M
% Owned: 56.34%
Shares Outstanding: 78.19M
TypeInstitutionsShares
Increased
40
1.34M
New
15
293.38K
Decreased
51
3.82M
Sold Out
20
933.71K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Lawson Macartney
President/Chief Executive Officer/Director
Brian Lian
Chief Financial Officer/IR Contact Officer
Greg Zante
Chief Operating Officer
Marianne Mancini
Director
Matthew Foehr
Independent Director
S. Kathy Rouan
Independent Director
Charles Rowland
Independent Director
J. Matthew Singleton
No Data
  • All
  • Financials
  • Insiders
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Webull offers kinds of Viking Therapeutics Inc stock information, including NASDAQ:VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.